Please use this identifier to cite or link to this item:
|Title:||Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617|
|Authors:||SATHEKGE MIKE; BRUCHERTSEIFER FRANK; LAWAL I; VORSTER MARIZA; KNOESEN OTTO; LENGANA T; BOSHOMANE T; MOKOALA K; MORGENSTERN ALFRED|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 46 no. 8 p. 1756-1757|
|Type:||Articles in periodicals and books|
|Abstract:||Brain metastases are not common in prostate cancer; they typically occur in patients with end-stage disease who are castrate-resistant. Patients with brain metastases have very limited survival. Traditionally, the mainstays of therapy have been surgical resection, chemotherapy and external beam radiotherapy. Recently, combination of 177Lu-Prostatespecific membrane antigen (PSMA)-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer (mCRPC) showed significant regression in the sizes and PSMA-ligand avidity of the lesions over time. Recent studies have demonstrated that targeted α-radiation therapy with 225Ac-PSMAligand can significantly benefit patients with mCRPC in the appropriate setting. Targeted α-radiation therapy may be more effective for the treatment of mCRPC, and has been shown, in limited number of patients, to be effective in the setting of resistant to 177Lu-PSMA-617 therapy.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.